Omnicell, Inc. $OMCL Shares Sold by First Light Asset Management LLC

Key Points

• First Light Asset Management reduced its Omnicell stake by 7.7%, selling 37,522 shares and retaining 452,324 shares valued at approximately $18.78 million. Institutional investors collectively own 97.7% of the company.
• Omnicell reported quarterly EPS of $0.94, exceeding the $0.47 consensus estimate, while revenue rose 7.4% year over year to $312.21 million. The company issued third-quarter 2026 EPS guidance of $0.35–$0.43.
• Analysts maintain a generally positive view, with seven Buy ratings and two Holds, producing a consensus “Moderate Buy” rating and an average price target of $57.86 versus the stock’s reported $33.64 price.

First Light Asset Management LLC lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 7.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 452,324 shares of the company's stock after selling 37,522 shares during the period. Omnicell makes up approximately 1.1% of First Light Asset Management LLC's portfolio, making the stock its 27th biggest holding. First Light Asset Management LLC owned approximately 0.99% of Omnicell worth $18,780,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Nykredit A S purchased a new position in shares of Omnicell in the 2nd quarter worth $26,000. Raymond James Financial Inc. purchased a new stake in Omnicell during the second quarter valued at about $26,000. Versant Capital Management Inc grew its position in Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company's stock valued at $44,000 after acquiring an additional 294 shares during the period. Clearstead Advisors LLC increased its stake in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company's stock worth $56,000 after acquiring an additional 1,218 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in Omnicell during the fourth quarter worth about $58,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Performance

Omnicell stock opened at $33.64 on Thursday. The stock's 50 day moving average price is $38.90 and its 200 day moving average price is $39.17. The firm has a market capitalization of $1.53 billion, a PE ratio of 40.05, a price-to-earnings-growth ratio of 0.85 and a beta of 0.97. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. Omnicell, Inc. has a one year low of $29.06 and a one year high of $55.00.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. During the same quarter last year, the company earned $0.45 earnings per share. Omnicell's revenue for the quarter was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, sell-side analysts expect that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on OMCL shares. Piper Sandler reaffirmed an "overweight" rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Zacks Research raised shares of Omnicell from a "strong sell" rating to a "hold" rating in a research report on Monday. KeyCorp restated an "overweight" rating on shares of Omnicell in a report on Monday, August 24th. Weiss Ratings raised shares of Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 18th. Finally, Wells Fargo & Company reduced their price target on shares of Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $57.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.